Logo image of DMAQ

DEEP MEDICINE ACQUISITI-CL A (DMAQ) Stock Fundamental Analysis

NASDAQ:DMAQ - Nasdaq - US2437331026 - Common Stock - Currency: USD

2.96  -5.43 (-64.72%)

After market: 2.98 +0.02 (+0.68%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to DMAQ. DMAQ was compared to 0 industry peers in the Unkown industry. The financial health of DMAQ is average, but there are quite some concerns on its profitability. DMAQ does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

DMAQ had negative earnings in the past year.
In the past year DMAQ has reported a negative cash flow from operations.
DMAQ Yearly Net Income VS EBIT VS OCF VS FCFDMAQ Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 -500K -1M -1.5M -2M

1.2 Ratios

Industry RankSector Rank
ROA -5.1%
ROE -22.17%
ROIC N/A
ROA(3y)-5.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
DMAQ Yearly ROA, ROE, ROICDMAQ Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 -5 -10 -15 -20

1.3 Margins

DMAQ does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DMAQ Yearly Profit, Operating, Gross MarginsDMAQ Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

DMAQ has less shares outstanding than it did 1 year ago.
Compared to 1 year ago, DMAQ has a worse debt to assets ratio.
DMAQ Yearly Shares OutstandingDMAQ Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M 15M
DMAQ Yearly Total Debt VS Total AssetsDMAQ Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of 0.08, we must say that DMAQ is in the distress zone and has some risk of bankruptcy.
There is no outstanding debt for DMAQ. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.08
ROIC/WACCN/A
WACCN/A
DMAQ Yearly LT Debt VS Equity VS FCFDMAQ Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 3.03 indicates that DMAQ has no problem at all paying its short term obligations.
A Quick Ratio of 3.03 indicates that DMAQ has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 3.03
Quick Ratio 3.03
DMAQ Yearly Current Assets VS Current LiabilitesDMAQ Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for DMAQ have decreased strongly by -466.67% in the last year.
EPS 1Y (TTM)-466.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
DMAQ Yearly Revenue VS EstimatesDMAQ Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
DMAQ Yearly EPS VS EstimatesDMAQ Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DMAQ reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DMAQ Price Earnings VS Forward Price EarningsDMAQ Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DMAQ Per share dataDMAQ EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DMAQ!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEEP MEDICINE ACQUISITI-CL A

NASDAQ:DMAQ (1/31/2024, 8:00:01 PM)

After market: 2.98 +0.02 (+0.68%)

2.96

-5.43 (-64.72%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners7.28%
Inst Owner Change-87.39%
Ins Owners65.87%
Ins Owner Change0%
Market Cap12.91M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.61
P/tB 5.61
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)-0.21
OCFYN/A
SpS0
BVpS0.53
TBVpS0.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -5.1%
ROE -22.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-5.47%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.03
Quick Ratio 3.03
Altman-Z 0.08
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-466.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-500%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-238.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-48.57%
OCF growth 3YN/A
OCF growth 5YN/A